首頁
Fate Therapeutics

3月 2026Fate Therapeutics的市場佔有率分析

Join Fate Therapeutics and become a vital member of our team working to develop groundbreaking cellular immunotherapies for patients suffering from cancer and autoimmune diseases. Our innovative research and cutting-edge technologies offer a unique opportunity for professionals to make a meaningful impact in the field of healthcare. Additionally, we foster a collaborative and inclusive culture […]

健康 > 生物技術和製藥

域名fatetherapeutics.com

成立年份2007

僱員51 - 200

年度營收$50M - $75M

Fate Therapeutics

Fate Therapeutics（包含公司地區）

fatetherapeutics.com

查看更多網站流量與參與度資訊

Fate Therapeutics截至 3月 2026 的總收入為 50M - 75M

Fate Therapeutics 熱門網域產生的總收入

Fate Therapeutics 熱門網域 3 年內的總收入

Fate Therapeutics 熱門網域的總收入

fatetherapeutics.com50M - 75M

透過銷售情報查看更多內容

Fate Therapeutics的熱門網域總造訪量

了解Fate Therapeutics市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

子公司細目

fatetherapeutics.com7.8K

透過銷售情報查看更多內容

Fate Therapeutics的熱門網域平均造訪時長

分析Fate Therapeutics參與度指標。

過去 3 個月平均造訪時長

子公司細目

fatetherapeutics.com00:01:58

透過銷售情報查看更多內容

Fate Therapeutics的熱門網域平均頁面瀏覽量

了解Fate Therapeutics如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

子公司細目

fatetherapeutics.com2.18

透過銷售情報查看更多內容

Fate Therapeutics按網域劃分的熱門競爭對手

3月 2026的熱門類似網站，依相似度排名

pharming.com公司名Pharming Group N.V.僱員201 - 500總部荷蘭, Leiden年度營收$200M - $500M訪問總量16.1K健康 > 生物技術和製藥

使用的熱門技術Fate Therapeutics

这些是Fate Therapeutics顶级域名使用的行业网站技术

電子郵件服務 (3)

Microsoft Exchange Online

小工具 (3)

Twemoji

付費廣告 (2)

Google Adsense

音訊視訊媒體 (2)

YouTube

更多技術

7

檢視所有

新聞與訊號來自Fate Therapeutics

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞Fate Therapeutics, Inc. attended event American Association for Cancer Research Annual Meeting on Apr 17th '22.SAN DIEGO, April 16, 2026 (GLOBE NEWSWIRE) - Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that preclinical data from the Company's next-generation, off-the-shelf CAR T-cell product candidate, FT839, will be featured at the American Association for Cancer Research Annual Meeting, being held in San Diego, CA on April 17-22, 2026.

新聞Fate Therapeutics, Inc. attends event Piper Sandler 37th Annual Healthcare Conference.SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) - Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that the Company will present at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 in New York, New York.